By Editorial Staff | September 28, 2026
In a significant recalibration of its oncology pipeline, pharmaceutical giant Merck & Co. has officially withdrawn its regulatory application for "I-DXd," an experimental antibody-drug conjugate (ADC) designed to treat small-cell lung cancer (SCLC). The move marks a sobering development for the company’s broader strategy to diversify its portfolio ahead of the impending patent expiration of its blockbuster immunotherapy, Keytruda. As the race to dominate the next generation of precision oncology heats up, the retreat of I-DXd underscores the rising bar for clinical efficacy and safety in the highly competitive space of B7-H3-targeted therapies.
The Core Challenge: A Crowded and Evolving Field
For years, Merck has aggressively pursued a "post-Keytruda" strategy, investing billions into ADCs—a sophisticated class of "guided-missile" cancer drugs that deliver potent chemotherapy directly to tumor cells while sparing healthy tissue. Through high-profile partnerships with Daiichi Sankyo and Kelun-Biotech, Merck has amassed a formidable arsenal of assets. However, not all assets are created equal, and the clinical landscape for SCLC has shifted rapidly.
I-DXd was intended to be a flagship offering, targeting the protein B7-H3, which is frequently overexpressed in aggressive, metastatic tumors. Yet, as recent clinical data from competing programs has emerged, I-DXd has struggled to maintain its competitive edge. The primary concern among analysts and regulators alike has been its safety profile, specifically regarding incidents of interstitial lung disease (ILD)—a form of severe, potentially fatal lung inflammation that has dogged several ADC programs in recent years.
Chronology of a Strategic Pivot
The trajectory of the I-DXd program has been defined by a series of high-stakes clinical milestones and competitive pressures:
- Early Development Phase: Following a lucrative partnership with Daiichi Sankyo, Merck accelerated I-DXd through early-stage trials, aiming to address the high unmet need in patients with extensive-stage small-cell lung cancer.
- The Rise of Competition: Throughout 2025 and into 2026, competing programs targeting the same B7-H3 protein began to report promising Phase 3 data, particularly in trials conducted in China.
- The Safety Signal: As I-DXd moved into larger-scale evaluations, clinical data indicated a susceptibility to ILD, prompting increased scrutiny from regulatory bodies, including the U.S. Food and Drug Administration (FDA).
- The Regulatory Realization: Facing a climate of heightened FDA oversight and the emergence of safer, more effective alternatives, Merck and Daiichi Sankyo determined that the likelihood of a successful, value-added approval had significantly diminished.
- September 2026 Withdrawal: The partners announced the formal withdrawal of their regulatory application, acknowledging that the clinical data, when weighed against the current competitive landscape, no longer justified an immediate market push.
Supporting Data: Why the Bar Has Been Raised
The failure of I-DXd to gain traction is inextricably linked to the success of its rivals. At recent oncology summits, presentations of data for two new B7-H3-targeted prospects—licensed to Roche and GSK, respectively—painted a stark contrast.
In Phase 3 studies, these competing agents, dubbed "riz-rez" (GSK) and "tam-peli" (Roche), demonstrated a robust ability to outperform standard chemotherapy in extensive-stage SCLC. Crucially, these trials have not yet shown the same incidence of interstitial lung disease that has plagued the I-DXd program.
According to RBC Capital Markets analyst Trung Huynh, the market sentiment toward I-DXd has soured as these safer alternatives progress. "We came away from recent presentations believing that both riz-rez and tam-peli had a better safety profile than I-DXd," Huynh noted in a recent briefing. The FDA’s increasingly stringent stance on accelerated approvals—which requires more than just preliminary, "limited" data—meant that I-DXd was facing an uphill battle that grew steeper with every successful trial readout from its competitors.
Furthermore, the recent FDA clearance of Amgen’s Imdelltra has set a new benchmark for what is considered "meaningful clinical advantage" in the SCLC space. As Cantor Fitzgerald’s Li Watsek observed, the bar has effectively been raised, and drugs that do not offer a clear, superior profile in both efficacy and safety are finding it nearly impossible to secure a foothold.
Official Responses and Industry Outlook
Merck’s decision to pull the application is viewed by industry experts not as a collapse of their ADC strategy, but as a tactical pruning of a portfolio that remains deep and diverse. While I-DXd stumbles, other assets in the Merck-Daiichi pipeline are thriving.
Specifically, the ADC "sac-TMT" remains a cornerstone of Merck’s future plans. With 17 global trials currently underway, Merck executives continue to tout sac-TMT as a transformative therapy for lung cancer. The company’s ability to pivot resources away from the struggling I-DXd program and toward higher-potential assets like sac-TMT is a testament to the agility required in modern pharmaceutical development.
Meanwhile, other players are surging. Zai Lab, with its candidate "zoci," is currently in pivotal testing and is widely considered the frontrunner to be the first ADC approved for SCLC. Ideaya Biosciences is also gaining ground, with plans to initiate late-stage trials by the end of 2026.
Implications: The Long-Term Vision
The withdrawal of I-DXd provides a masterclass in the complexities of oncology drug development. Three key implications emerge from this development:
1. The Safety-First Regulatory Environment
The FDA is no longer willing to fast-track oncology drugs based on surrogate endpoints if the safety profile carries significant morbidity risks like ILD. This "heightened scrutiny" means that developers must prioritize toxicity management as heavily as tumor shrinkage.
2. The "Fast-Follower" Advantage
While being first to market is traditionally the goal, the recent successes of Roche and GSK prove that being a "fast follower" with a superior safety profile can effectively leapfrog earlier, more toxic programs. The competitive landscape for B7-H3 is now defined by those who can provide the cleanest clinical data.
3. Diversification as a Risk Mitigation Tool
Merck’s strategy of "multiple bets" is being validated by this event. By diversifying across numerous ADCs and partnership models (Daiichi, Kelun-Biotech, etc.), Merck is insulated from the failure of any single program. While I-DXd is a setback, the potential of the remaining pipeline suggests that the overall oncology strategy remains robust.
What Lies Ahead for I-DXd?
Though the lung cancer application has been pulled, the story for I-DXd is not necessarily over. Merck and Daiichi Sankyo are continuing to evaluate the drug in two other Phase 3 trials: one for prostate cancer and another for esophageal squamous cell carcinoma. The results from these trials will be the final arbiter of whether I-DXd finds a second life in different tumor microenvironments where its efficacy might outweigh its safety profile.
As 2026 draws to a close, the pharmaceutical industry continues to watch Merck closely. The company’s transition from a Keytruda-dependent business to an ADC-focused powerhouse is a high-stakes evolution. The I-DXd withdrawal serves as a reminder that in the realm of precision medicine, the path to the clinic is rarely a straight line—it is a rigorous, data-driven marathon where only the most robust therapies reach the finish line.
